Cargando…

RTK Inhibitors in Melanoma: From Bench to Bedside

SIMPLE SUMMARY: Receptor tyrosine kinases (RTKs) have long been demonstrated to play key roles in melanoma development. RTK activation requires dimerization and intracellular tyrosine trans-phosphorylation leading to downstream signaling pathways activation. As RTKs show different structures, mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabbah, Malak, Najem, Ahmad, Krayem, Mohammad, Awada, Ahmad, Journe, Fabrice, Ghanem, Ghanem E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038208/ https://www.ncbi.nlm.nih.gov/pubmed/33918490 http://dx.doi.org/10.3390/cancers13071685

Ejemplares similares

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
por: Najem, Ahmad, et al.
Publicado: (2022)

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies
por: Najem, Ahmad, et al.
Publicado: (2023)

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
por: Sabbah, Malak, et al.
Publicado: (2023)

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
por: Krayem, Mohammad, et al.
Publicado: (2019)

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018)

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value
por: Najem, Ahmad, et al.
Publicado: (2021)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
por: Krayem, Mohamad, et al.
Publicado: (2020)

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512
por: Krayem, Mohammad, et al.
Publicado: (2020)

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms
por: Soumoy, Laura, et al.
Publicado: (2020)

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
por: Soumoy, Laura, et al.
Publicado: (2020)

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
por: Kehagias, Pashalina, et al.
Publicado: (2022)

Cytokine Landscape in Central Nervous System Metastases
por: Marin, Julie, et al.
Publicado: (2022)

Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
por: Soumoy, Laura, et al.
Publicado: (2019)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research
por: Cogels, Morgane M., et al.
Publicado: (2021)

B-Raf and the inhibitors: from bench to bedside
por: Huang, Tiangui, et al.
Publicado: (2013)

Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
por: de Bakker, Tycho, et al.
Publicado: (2022)

Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas
por: Kindt, Nadège, et al.
Publicado: (2017)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Sepsis: From Bench to Bedside
por: Silva, Eliézer, et al.
Publicado: (2008)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

The Impact of MITF on Melanoma Development – News from Bench and Bedside
por: Roider, Elisabeth, et al.
Publicado: (2014)

Olutasidenib: from bench to bedside
por: Venugopal, Sangeetha, et al.
Publicado: (2023)

Efflux pump inhibitors for bacterial pathogens: From bench to bedside
por: Sharma, Atin, et al.
Publicado: (2019)

Research in Sickle Cell Disease: From Bedside to Bench to Bedside
por: Salinas Cisneros, Gabriel, et al.
Publicado: (2021)

Dystonia and Cerebellum: From Bench to Bedside
por: Morigaki, Ryoma, et al.
Publicado: (2021)

Alcohol in Psoriasis—From Bench to Bedside
por: Szentkereszty-Kovács, Zita, et al.
Publicado: (2021)

Variable ventilation from bench to bedside
por: Huhle, Robert, et al.
Publicado: (2016)

Biology of Cholangiocytes: From Bench to Bedside
por: Yoo, Kyo-Sang, et al.
Publicado: (2016)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors
por: Gardner, Christopher R., et al.
Publicado: (2023)

Drug addiction: from bench to bedside
por: Cheron, Julian, et al.
Publicado: (2021)

Cancer proteomics: from bench to bedside
por: Timms, J F
Publicado: (2008)

Indirect Calorimetry: From Bench to Bedside
por: Gupta, Riddhi Das, et al.
Publicado: (2017)

Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)

Cancer photo-immunotherapy: from bench to bedside
por: Wang, Miao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aheono5vj40ttfgainnomkrjm8